Unknown

Dataset Information

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.


ABSTRACT:

Introduction

Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the long-term effectiveness and safety of adalimumab biosimilars for treating psoriasis in real-world settings are uncertain and may be a barrier to widespread usage.

Methods and analysis

This study aims to compare the drug survival and safety of adalimumab biosimilars to adalimumab originator for the treatment of psoriasis. We will use both routinely collected healthcare databases and dedicated pharmacovigilance registries from the PsoNet initiative, including data from the UK, Franc

SUBMITTER: Phan DB 

PROVIDER: S-EPMC10351260 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature